HEMATOLOGY

During a live Twitter Spaces event hosted by Targeted Oncology, Naveen Pemmaraju, MD, explained key abstracts from ASH 2022 and how these data have influenced recent approvals in the hematology field.

In an interview with Targeted Oncology, Zahra Mahmoudjafari, PharmD, BCOP, discussed the post hoc analysis from the REACH2 trial and highlighted the key takeaways.

Research shows a high occurrence of ibrutinib-related cardiotoxicity in patients with cancer. This is the first study showing such evidence.

During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed biologic phases of chronic graft-vs-host disease and which therapies are available for patients who do not respond to steroids.

At 1 year, the GVHD-and–relapse-free survival achieved with Orca-Q was 75%, which was noted to compare favorably with prior data reported in context of myeloablative conditioning , haploidentical stem cell transplant, and posttransplant cyclophosphamide.

Ruxolitinib elicited higher responses at day 28 compared with best available therapy in most cytopenia-based subgroups and had durable responses at day 56, according to a post hoc analysis of the REACH2 trial.

According to findings presented at the 2023 Transplantation & Cellular Therapy Meetings, experts did not identify clear correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib in patients with graft-vs-host-disease.

In 8 patients with various hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors, Orca-T led to a 100% survival rate.

The phase 3 REACH2 trial showed that early treatment with ruxolitinib 10 mg led to higher response rates vs that seen with the best available therapy in patients with grade II-IV steroid-refractory acute graft-vs-host disease.

Looking at a retrospective analysis of data from a single-center, the use of ruxolitinib decreased non-relapse mortality and improved overall survival for patients with steroid-refractory acute graft-vs-host-disease.

Final safety and efficacy read outs of the EQUATE trial show durable clinical responses and a favorable safety profile for acute graft-vs-host disease.

The phase 1/2 BRUIN study of pirtobrutinib led to promising early efficacy in patients with B-cell malignancies who were heavily pretreated with richter transformation.

During a Targeted Oncology™ Case-Based Roundtable™ event, Javier Pinilla-Ibarz, MD, PhD, discussed risk factors and treatment options for tumor lysis syndrome.

Stephen Oh, MD, PhD, gives a comprehensive review of the available treatment options for myelofibrosis.

An expert hematologist discusses important molecular targets in myelofibrosis, and when to consider transplant.

In an interview with Targeted Oncology, Jeremy Abramson, MD, discussed findings of the phase 3 TRANSFORM study which were presented at the 2022 American Society of Hematology Annual Meeting.

Ben Derman, MD, discussed the rationale for an ongoing clinical trial evaluating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.

Tamibarotene has received fast track designation from the FDA for use in patients with higher-risk myelodysplastic syndrome. The agent is being further evaluated in the phase 3 SELECT MDS-1 trial.

Stephen Oh, MD, PhD, explains the different types of myelofibrosis and describes the signs and symptoms.

John M. Burke, MD, highlights progress in the field of hematology and oncology presented at the 64th American Society of Hematology Annual Meeting and Exposition.

Srikanth Nagalla, MD, MS, describes initiatives to improve the talent pipeline for hematology staff at all levels.

In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.

During a Targeted Oncology case-based roundtable event, Hana Safah, MD, discussed chronic graft-vs-host disease in terms of diagnosis, phases, risk assessment, and treatment options.

In an interview with Targeted Oncology, Marlise Luskin, MD, MSCE, discussed the challenges of treating adult and elderly patients with acute lymphoblastic leukemia and where new research in the space is headed.

VITAL study results reveal survival advantage of birtamimab for patients with Mayo Stage IV amyloid light chain amyloidosis.

Clinical benefit has been achieved with zanubrutinib treatment in patients B-cell malignancies who were intolerant to acalabrutinib.

The SINTRA-REV trial showed lower risk of transfusion dependency in patients with MDS treated with lenalidomide.

COMMODORE study results are positive for its two primary end points of stable hemolysis control and transfusion avoidance in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab.

Fast and durable response were seen in patients with Waldenström Macroglobulinemia who received the combination of ibrutinib and venetoclax.

Phase 1/2 BRUIN study results show high response rates in patients with Waldenström macroglobulinemia who were treated with pirtobrutinib.